Magic mushroom compound tested to restore joy in depressed patients

NCT ID NCT07490353

First seen Apr 18, 2026 · Last updated May 01, 2026 · Updated 3 times

Summary

This early-stage study explores whether psilocybin, the active ingredient in magic mushrooms, can reduce anhedonia (loss of pleasure) in people with major depression. 85 participants, including healthy volunteers, will receive psilocybin in two sessions—one with a drug that blocks the psychedelic effects. Brain scans and questionnaires will measure changes in reward processing, well-being, and mood. The goal is to understand how the psychedelic experience itself contributes to any anti-anhedonic benefits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANHEDONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry

    RECRUITING

    Vienna, State of Vienna, 1160, Austria

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.